Werewolf Therapeutics Added to the Nasdaq Biotechnology Index

December 14, 2021

CAMBRIDGE, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative

March 7, 2024

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

WATERTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) Read More

March 6, 2024

Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference

WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) Read More

March 5, 2024

Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024

WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) Read More

Share this article: